Merck & Co., Inc. logo

Merck & Co., Inc.

MRK
Pharmaceutical Preparations
Last filing · Quarter 2 · Jun 30, 2026
Statement
Order
Format
% Change
Rows
USD ($)
$ in Millions
LTMDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017Dec 31, 2016Dec 31, 2015Dec 31, 2014Dec 31, 2013Dec 31, 2012Dec 31, 2011Dec 31, 2010Dec 31, 2009
Sales
66,569
65,011
64,168
60,115
Costs, Expenses and Other
                  
Cost of sales
17,996
16,382
15,193
16,126
Selling, general and administrative
11,135
10,733
10,816
10,504
Research and development
30,453
15,789
17,938
30,531
Restructuring costs
606
889
309
599
Equity income from affiliates
-
-
-
-
U.S. Vioxx Settlement Agreement charge
-
-
-
-
Other (income) expense, net
(431)
(151)
24
(466)
Total costs, expenses and other
60,621
43,944
44,232
58,226
Income Before Taxes
5,948
21,067
19,936
1,889
Taxes on Income
2,779
2,804
2,803
1,512
Net Income
3,169
18,263
17,133
-
Net Income from Continuing Operations
-
-
-
377
Less: Net Income Attributable to Noncontrolling Interests
(4)
9
16
12
Net Income from Continuing Operations Attributable to Merck & Co., Inc.
-
-
-
365
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests
-
-
-
0
Net Income Attributable to Merck & Co., Inc.
3,173
18,254
17,117
365
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders
                  
Income from Continuing Operations (in dollars per share)
-
-
-
0.14
Income from Discontinued Operations (in dollars per share)
-
-
-
0
Preferred Stock Dividends
-
-
-
-
Net Income Available to Common Shareholders
-
-
-
-
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)
1.26
7.3
6.76
0.14
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders
                  
Income from Continuing Operations (in dollars per share)
-
-
-
0.14
Income from Discontinued Operations (in dollars per share)
-
-
-
0
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)
1.25
7.28
6.74
0.14